Roger M. Perlmutter

Roger M. Perlmutter is an American physician-scientist and biotechnology executive renowned for his transformative leadership in the pharmaceutical industry. His career, spanning academia and major corporations like Merck & Co. and Amgen, has been pivotal in advancing immunology and bringing groundbreaking therapies to market. Perlmutter is particularly celebrated for overseeing the development of the blockbuster immunotherapy drug Keytruda (pembrolizumab), which revolutionized the treatment of multiple cancer types. His scientific acumen and strategic vision have established him as a central figure in modern drug discovery and biotechnology innovation.

Early life and education

He was born in Los Angeles and pursued his undergraduate education at Reed College in Portland, Oregon, earning a Bachelor of Arts degree. Perlmutter then entered a combined M.D./Ph.D. program, receiving his Ph.D. in chemistry from the California Institute of Technology under the mentorship of noted biologist Lee Hood. He completed his medical doctorate at the University of Pennsylvania School of Medicine, followed by residency training in internal medicine at the Brigham and Women's Hospital in Boston. His postdoctoral fellowship was conducted in the laboratory of David Baltimore at the Massachusetts Institute of Technology, where he further honed his expertise in molecular immunology.

Career at Merck & Co.

Perlmutter joined Merck & Co. in 1997 as senior vice president of Basic Research, after serving as chairman of the Department of Immunology at the University of Washington School of Medicine. At Merck, he rose to become executive vice president and president of Merck Research Laboratories, a position he held from 2001 to 2013. During this tenure, he reoriented the company's research strategy towards biologics and immunology, decisively championing the acquisition of Schering-Plough and its asset pembrolizumab. His leadership was instrumental in the rapid clinical development and subsequent FDA approvals of Keytruda, which became a foundational therapy in oncology. He also oversaw the development and launch of other significant drugs, including the HPV vaccine Gardasil and the HIV treatment Isentress.

Leadership at Amgen and Eikon Therapeutics

In 2014, Perlmutter was appointed executive vice president of Research and Development at Amgen, one of the world's largest independent biotechnology companies. He guided Amgen's expansive portfolio, emphasizing cardiovascular disease, oncology, and neuroscience, and oversaw the approval of therapies like Repatha (evolocumab). After retiring from Amgen in 2022, he assumed the role of CEO at the startup Eikon Therapeutics, a company leveraging advanced microscopy and machine learning for drug discovery. His move to Eikon Therapeutics signified a commitment to pioneering new technological platforms within the biopharmaceutical sector.

Scientific contributions and research focus

His foundational research has profoundly influenced the understanding of lymphocyte development and the immune system. Early work focused on the genetic mechanisms controlling T-cell receptor and immunoglobulin gene rearrangement, critical for adaptive immunity. This academic work provided a scientific foundation for his later industry career, where he applied deep immunological insights to therapeutic development. His research focus has consistently centered on harnessing the immune system to treat disease, most notably through immune checkpoint inhibitors like Keytruda, which block the PD-1 pathway. His contributions extend to vaccinology, autoimmune disease, and the application of genomics to personalized medicine.

Awards and honors

Perlmutter's work has been recognized by many prestigious institutions. He was elected a member of the National Academy of Sciences in 2001 and the National Academy of Medicine in 2002. He has received the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation and has been honored with a Distinguished Alumni Award from the California Institute of Technology. His leadership in the pharmaceutical industry has also been acknowledged through numerous executive and lifetime achievement awards from organizations within the biotechnology and business communities.

Category:American immunologists Category:American businesspeople in the pharmaceutical industry Category:California Institute of Technology alumni Category:University of Pennsylvania alumni Category:1953 births Category:Living people